Monosodium urate crystal deposition arthropathy part I: Review of the stages and diagnosis of gout

Advanced Studies in Medicine

Volumn 5, Issue 3, 2005, Pages 133-138

  Schumacher Jr , H Ralph ^a,b   Wortmann, Robert L ^c   Lewis Jr , C S ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of Oklahoma Tulsa College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; DIURETIC AGENT; IODINATED CONTRAST MEDIUM; URATE; URIC ACID; URICOSURIC AGENT;

ARTHROPATHY; CLINICAL FEATURE; COHORT ANALYSIS; CRYSTAL STRUCTURE; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGICAL DATA; GOUT; HIGH RISK POPULATION; HYPERURICEMIA; INCIDENCE; NEPHROLITHIASIS; PATHOGENESIS; POSTMENOPAUSE; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SEX RATIO; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 16344364675     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Kerr LD. Inflammatory arthritis in the elderly. Mt Sinai J Med. 2003;70:23-26.
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the US. Artois Rheum. 1998;41:778-799.
3. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-2406.
4. Monev SD. How should hyperuricemia be treated in a patient with allopurinol hypersensitivity. Cleve Clin J Med. 2001;68:597-598.
5. Eliis S, Isenberg D. Controlling hyperuricemia in general practice. Practitioner. 1999;243:880-891.
6. Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Ruddy S, Harris ED, Sledge CB, eds. Kelley's Textbook of Rheumatology, ed 6. Philadelphia, Pa: WB Saunders; 2001:1339-1376.
7. Campion ES, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-426.
8. Davis JC. A practical approach to gout: current management of an "old" disease. Postgrad Med. 1999;106:115-123.
9. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002;69:8:594-608.
10. Emmerson BT. Abnormal urate excretion associated with renal and systemic disorders, drugs, and toxins. In: Kelley WN, Weiner IM, eds. Handbook of Experimental Pharmacology, vol 51: Uric acid. New York: Springer-Verlag; 1978:287-324.
11. O'Sullivan JB. Gout in a New England town: a prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166-169.
12. Beck LH. Requiem for gouty nephropathy. Kidney Int. 1980;30:280-287.
13. Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67:1133-1148.
14. Fessel JW. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74-82.
15. Effinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-1389.
16. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti Heart Study. J Hum Hypertens. 1994;8:677-681.
17. Selby JV, Friedman GD, Quesenberry CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol and other serum chemistries. Am J Epidemiol. 1990;131:1017-1027.
18. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: The Framingham study. J Clin Epidemiol. 1988;41:237-242.
19. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemial. 1995;141:637-044.
20. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281-286.
21. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10:403-409.
22. Mazzali M, Hughes J, Kim Y, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106.
23. Lee J, Sparrow D, Vokonas PS, et al. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. Am J Epidemiol. 1995;142:288-294.
24. Gelber AC, Klag MJ, Mead LA, et al. Gout and risk for subsequent coronary heart disease: the Meharry-Hopkins Study. Arch Intern Med. 1997;157:1436-1440.
25. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemio with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA Study. Ann Epidemiol. 1998;8:250-261.
26. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol. 2000;16:779-789.
27. Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis. 1997;30:928-931.
28. Breckenridge A. Hypertension and hyperuricemia. Lancet. 1966;1:15-18.
29. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricemia and risk of cardiovascular disease and overall death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand. 1988;224:549-555.
30. Persky VW, Dyer AR, Idris-Soven E, et al. Uric acid: a risk factor for coronary heart disease? Circulation. 1979;59:969-977.
31. Langford HG, Blaufox MD, Borhani NO, et al. Is thiazide-produced uric acid elevation harmful? Analysis of dato from the Hypertension Detection and Follow-up Program. Arch Intern Med. 1987;147:645-649.
32. Casiglia E, Spolaore P, Ginocchio G, et al. Predictors of mortality in very old subjects aged 80 years of over. Eur J Epidemiol 1993;9:577-586.
33. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635-639.
34. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-1587.
35. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990;16:539-550.
36. Anton FM, Garcia Puig J, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 on the renal handling of urate metabolism. Metabolism. 1986;35:343-348.
37. Veerapen K, Schumacher HR, van Linthoudt D, Neilson EG, Wang F. Tophaceous gout in young patients with systemic lupus erythematosus. J Rheumatol. 1993;20:721-724.
38. MacFarlane DG, Dieppe PA. Diuretic-induced gout in elderly women. Br J Rheumatol. 1985;24:155-157.
39. Ter Borg EJ, Rasker JJ. Gout in the elderly, a separate entity? Ann Rheum Dis. 1987;46:72-76.
40. Agudelo CA, Wise CM. Crystal-associated arthritis. Clin Geriatr Med. 1998;14:495-513.
41. Puig JG, Michan AD, Jimenez JL, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991;151:726-732.
42. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-979.
43. Wluka AE, Ryan PF, Miller AM, et al. Post cardiac transplantation gout: Incidence of therapeutic complications. J Heart lung Transplant. 2000;19:951-956.
44. Simkin PA. When, why, and how should we quantify the excretion rate of urinary uric acid? J Rheumatol. 2001;28:1207-1210.
45. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501-1505.
46. Lowry GV, Fan PG, Bluestone R. Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine. 1988;67:335-343.
47. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricaemia. Am Fam Physician. 1999;59:925-934.
48. Fam AG. Gout in the elderly: clinical presentation and treatment. Drugs Aging. 1998;13:229-243.
49. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-325.
50. Hadler NM, Franck WA, Bress NM, et al. Acute polyarticular gout. Am J Med. 1974;56:715-719.
51. Van Doornum S, Ryan PFJ. Clinical manifestations of gout and their management. Med J Aust. 2000;172:493-497.
52. Yu TF. Nephrolithiasis in patients with gout. Postgrad Med. 1978;63:164-170.
53. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59:1799-1806.
54. Pal B, Foxall M, Dysart T, Carey F, Whittaker M. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol. 2000;19:21-25.
55. Becker MA, Jolly M. Clinical gout and the pathogenesis of hyperuricemia. Chapter 13, section XII: Metabolic Bone and Joint Disease. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Conditions. A Textbook of Rheumatology, 15th ed, vol 2. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: 2303-2339.
56. Schumacher HR, Reginato AJ. Atlas of Synovial Fluid Analysis and Crystal Identification. Philadelphia, Pa: Lea & Febiger; 1991:257.
57. Agudelo CA, Weinberger A, Schumacher HR, Turner R, Molina J. Definitive diagnosis or gout by identification of urate crystals in asymptomatic metatarsaophalangeal joints. Arthritis Rheum. 1979;22:559-560.
58. Weinberger A, Schumacher HR, Weiner DJ. Intraarticular microfilariae in laboratory animals. Arthritis Rheum. 1979;22: 1142-1145.
59. Dieppe PA, Swan A. Identification of crystals in synovial fluid. Ann Rheum Dis. 1999;58:261-263.
60. Schumacher HR, Somlyo AP, Tse RL, Maurer K. Arthritis associated with apatite crystals. Ann Intern Med. 1977;87:411-416.
61. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med. 1996;100(suppl 2A):46S-52S.
62. Petrocelli A, Wong AL, Sweezy RL. Identification of pathologic synovial fluid crystals on Gram-Stains. J Clin Rheumatol. 1998;4:103-105.
63. Aubaker MY, Querubin RN, Holland W, et al. Coexistence of acute gout and septic arthritis. Arthritis Rheum. 2000; 43(suppl 9):S189.
64. Fam AG. Strategies and controversies in the treatment of gout and hyperuricemia. Baillieres Clin Rheumatol. 1990;42:177-192.
65. McCarty DJ. Intractable gouty arthritis. Hosp Pract. 1987;22:191-209.
66. Fam AG. Managing problem gout. Ann Acad Med Singapore. 1998;27:93-99
67. Wallace SL, Bernstein D, Diamond H. Diagnostic value of colchicines therapeutic trial. JAMA. 1967:325-528.
68. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900.
69. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout [letter]. Am Rheum Dis. 1997;56:696-697.
70. Schlesinger N, Baker DG, Schumacher HR Jr. Serum uric acid during bouts of acute gouty arthritis [letter]. J Rheumatol. 1997;24:2265-2266.
71. McCarty DJ. Gout without hyperuricemia. JAMA. 1994;271:302-303.
72. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep. 2001;3:29-35.
73. Fam AG. "Problem" gout: Clinical challenges, effective solutions. J Musculoskelet Med. 1997;14:63-77.
74. Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentration during acute gouty arthritis. J Rheumatol. 2002;29: 1950-1953.